EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting lactylation and the STAT3/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma

Qun Chen, Hao Yuan, Michael S Bronze, Min Li

Journal of Clinical Investigation · 01.04.2025 · 135 (7)

DOI: 10.1172/jci191422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.04.2025. Verfasst von Qun Chen und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, STAT3 Transcription Factor, Pancreatic Neoplasms, Chemokine CCL2. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic reprogramming in pancreatic ductal adenocarcinoma (PDAC) fosters an immunosuppressive tumor microenvironment (TME) characterized by elevated lactate levels, which contribute to immune evasion and therapeutic resistance. In this issue of the JCI , Sun, Zhang, and colleagues identified nonhistone ENSA-K63 lactylation as a critical regulator that inactivates PP2A, activates STAT3/CCL2 signaling, recruits tumor-associated macrophages (TAMs), and suppresses cytotoxic T cell activity. Targeting ENSA-K63 lactylation or CCL2/CCR2 signaling reprograms the TME and enhances the efficacy of immune checkpoint blockade (ICB) in PDAC preclinical models. This work provides critical insights into the metabolic-immune crosstalk in PDAC and highlights promising therapeutic strategies for overcoming immune resistance and improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalSTAT3 Transcription FactorPancreatic NeoplasmsChemokine CCL2Drug Resistance, NeoplasmImmunotherapySignal TransductionNeoplasm ProteinsHumansAnimalsTumor MicroenvironmentMice

Substanzen

STAT3 Transcription FactorSTAT3 protein, humanChemokine CCL2CCL2 protein, humanNeoplasm Proteins

Förderung

  • NCI NIH HHS

Zitieren

APA

Chen, Q., Yuan, H., Bronze, M. S., & Li, M. (2025). Targeting lactylation and the STAT3/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma. Journal of Clinical Investigation, 135(7). https://doi.org/10.1172/jci191422

Vancouver

Chen Q, Yuan H, Bronze MS, Li M. Targeting lactylation and the STAT3/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma. Journal of Clinical Investigation. 2025;135(7). doi:10.1172/jci191422

BibTeX
@article{Chen2025,
  author = {Chen, Qun and Yuan, Hao and Bronze, Michael S and Li, Min},
  title = {Targeting lactylation and the STAT3/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {7},
  doi = {10.1172/jci191422}
}
Kostenlos starten →